"Lawsuits require the same dedication to preparation and I will not
be outworked. It’s just that simple."
- Tommy Fibich
About Tommy Fibich
Tommy Fibich is known and respected among trial lawyers as one of the true
gentlemen of his profession. Tommy is a fearless trial lawyer, having
represented clients successfully in diverse legal matters, ranging from
catastrophic personal injury lawsuits to claims alleging fraud, product
liability, and commercial torts. He is known for his consummate preparation
and his tireless work ethic. These are the hallmarks of any successful
trial lawyer, and Tommy has a well-earned reputation among members of
both the plaintiff and the defense bar as a proficient and skillful advocate.
Fibich has devoted the last two decades of his career to representing individuals in
personal injury and
product liability lawsuits. When a corporate defendant is served with papers signed by Tommy
Fibich, it sends a clear and unmistakable message that the case will be
vigorously prosecuted and the defendant held accountable for its conduct.
Tommy prides himself on his ability to identify and implement a successful
trial strategy that fits the unique facts of each case.
His track record of success is a testament to his skills both inside and
outside the courtroom.
Award-Winning Legal Representaiton
Attorney Fibich's professional awards are just one measure of his esteemed
reputation among legal peers.
These hallmarks of excellence include:
- University of Houston Law School 2004 Alumnus of the Year
- Member of Multi-million Dollar Advocates Forum®
Selected for inclusion in Thomson Reuters
Super Lawyers® Magazine from 2003-2015
- Designated as a Thomson Reuters Top 100 Super Lawyer - Houston
- Nominated by the Texas Association of Civil Trial Specialists for Lifetime
Achievement in the practice of law
- Elected to the American Board of Trial Advocates
- Board Certified by the Texas Board of Legal Specialization in Civil Trial Law
- Designated by his peers to the highest standard of professionalism in the
profession - preeminent recognition in legal ability and ethical standards
for 25 consecutive years by Martindale-Hubbell®.
Providing Trustworthy Legal Counsel
Tommy is proud to have been raised in a humble but honest home in Bruni,
Texas. He attended High School in San Antonio and graduated from the University
of Texas in Austin. Following service in the United States Army, he entered
the University of Houston law school, where he graduated in 1974 as a
member of the Order of Barons, the highest scholastic honorary society.
Tommy is cognizant of the fact that he represents people who have little
chance of obtaining justice without the Fibich legal team.
"I have to say that the diversity of experiences I had in growing
up and my relationships with people of all walks of life have afforded
me a great background for picking the right jurors in jury selection as
well as communicating with them in trial." While today he is a leader in his profession, Tommy Fibich never forgets
where he came from.
Tommy Fibich Has Gone Up Against Large Companies
Tommy Fibich was recently in trial against Abbott Laboratories, Inc. in
federal court in St. Louis, Missouri. Tommy Fibich was lead trial counsel
in the drug product liability case which alleged that Abbott’s drug
Depakote was ingested during pregnancy and ultimately caused severe birth
defects to the child.* This was the first Depakote birth defect case to
go to trial, and there are approximately 850 Depakote cases pending across
Abbott Laboratories previously pleaded guilty and agreed to pay $1.5 billion
to resolve its criminal and civil liability arising from the company’s
unlawful promotion of Depakote for uses not approved as safe and effective
by the Food and Drug Administration, according to the U.S. Justice Department.**
D.W.K., a minor by Mary Kaleta and Daniel Kaleta, individually as parents
and next friends of D.W.K. v. Abbott Laboratories, Inc., no. 14-cv-847-NJR-SCW, United States District Court, Southern District
of Illinois, East St. Louis Division.
published May 7, 2012.